A supply chain that could end the pandemic

Post Reports

The Washington Post

Daily News, Politics, News

4.4 • 5.1K Ratings

🗓️ 10 December 2020

⏱️ 29 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

When the first coronavirus vaccine is approved for emergency use, officials across the country will embark on a finely orchestrated, high-stakes process to distribute and administer doses. Meet the people inside the supply chain that could end the pandemic.

Once you have a vaccine, you have to get it to the masses. That’s the hard part.

A vaccine manufacturer. A shipper. A state health official. A dry-ice guy. Host Martine Powers and producer Linah Mohammad take us inside the supply chain and speak to the people responsible for making the life-saving vaccine program work. In this episode, we explore how each part of the chain is preparing — from approval and manufacturing, to climate-controlled delivery reliant on dry ice, to how stores are readying themselves for the first shipment.

Learn about the potential kinks that may show up in the chain and what it takes to overcome those hurdles.

What you need to know about the coronavirus vaccine, and what to watch this week.

Subscribe to The Washington Post: https://postreports.com/offer

Transcript

Click on a timestamp to play from that location

0:00.0	From the newsroom of the Washington Post.
0:05.0	Hi, this is Tracy Jamm, Collie from the Post.
0:08.0	I'm a president for Up Power You.
0:10.0	Hi, it's Rodent Devon, Up The Washington Post.
0:13.0	This is Post Reports.
0:15.0	I'm Martin Powers.
0:18.0	It's Thursday, December 10.
0:24.0	Today, the coronavirus vaccine supply chain,
0:27.0	all the ins, outs, and obstacles.
0:30.0	Good morning.
0:37.0	Today, we will be considering whether to make available to millions of Americans,
0:41.0	and as yet, investigational vaccine that has been developed, tested,
0:46.0	and reviewed in record time, with additional testing still underway in ongoing study.
0:52.0	Today, an FDA advisory committee is meeting to discuss whether to give emergency approval
0:58.0	to the first coronavirus vaccine here in the US.
1:01.0	The American public demands and deserves a rigorous, comprehensive, and independent review of the data.
1:08.0	And that's what FDA physicians and scientists, all of us, career public health servants,
1:14.0	have been doing over days, nights, weekends, and yes, over the Thanksgiving holiday.
1:21.0	We have all been hearing about this vaccine, the one developed by Pfizer and Beyond Tech.
1:27.0	It requires two doses, it has to be kept at super cold temperatures,
1:31.0	it's apparently 95% effective in preventing people from getting COVID-19.
1:36.0	And it's looking likely that the FDA will say, yes, we can start administering this vaccine on an emergency basis,
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from The Washington Post, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Washington Post and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.